Clinical Trial Update: A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) [Phase 3]

View source ↗

Summary

This document describes a long-term extension Phase 3 trial of dazodalibep for Sjögren's syndrome, sponsored by Amgen, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• Dazodalibep (dazodalibep)

Snippet

Sponsor: Amgen | Conditions: Sjögren's Syndrome | Phase 3 | Status: RECRUITING